Combined antiangiogenic and mammalian target of rapamycin inhibitor targeted therapy in metaplastic breast cancer harboring a PIK3CA mutation

Keyphrases

• Targeted Therapy 100%
• Antiangiogenic 100%
• MTOR Inhibitor 100%
• PIK3CA mutation 100%
• Metaplastic Breast Cancer 100%
• Codon 50%
• Stem Cells 25%
• Tumor 25%
• Clinical Course 25%
• Bevacizumab 25%
• Breast Cancer Subtypes 25%
• Molecular Profiling 25%
• Temsirolimus 25%
• Partial Remission 25%
• Mammalian Target of Rapamycin (mTOR) 25%
• Disease Course 25%
• TP53 mutation 25%
• Chemoresistant 25%
• Exon 10 25%
• Exon 8 25%
• Kinase Inhibitor 25%
• Novel Targeted Therapy 25%
• Pegylated Liposomal Doxorubicin 25%
• Older African American Women 25%
• Scientific Rationale 25%
• Secondary Site 25%
• Target of Rapamycin Kinase 25%
• Rare Breast Cancer 25%
• Extremely Rare 25%
• Heterogeneous Phenotype 25%
• Molecularly Matched Therapy 25%

Medicine and Dentistry

• Targeted Therapy 100%
• Breast Cancer 100%
• Antiangiogenic 100%
• Mammalian Target of Rapamycin Inhibitor 100%
• Exon 40%
• Codon 40%
• Diseases 20%
• Disease Course 20%
• Molecular Profiling 20%
• Bevacizumab 20%
• Temsirolimus 20%
• Doxorubicin 20%
• Stem Cell 20%
• Tumor 20%